UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000005994 |
|---|---|
| Receipt number | R000007091 |
| Scientific Title | Efficacy and safety of sitagliptin in patients with type 2 diabetes: a multicentre observational study |
| Date of disclosure of the study information | 2011/07/18 |
| Last modified on | 2016/12/12 11:39:25 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Efficacy and safety of sitagliptin in patients with type 2 diabetes: a multicentre observational study
Acronym
BIRIKEN-2 Study (Blood glucose Investigation and Reduction In Kansai area by ENdocrinologist-2 Study)
Scientific Title
Efficacy and safety of sitagliptin in patients with type 2 diabetes: a multicentre observational study
Scientific Title:Acronym
BIRIKEN-2 Study (Blood glucose Investigation and Reduction In Kansai area by ENdocrinologist-2 Study)
Region
| Japan |
Condition
Condition
Diabetes mellitus
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The study aims to evaluate efficacy and safety of a DDP-4 inhibitor, sitagliptin, in patients with type 2 diabetes. In addition, stratified analyses by treatment (monotherapy vs combination therapy), and patient background will be conducted to identify patients who can benefit from treatment with sitagliptin.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
Changes in HbA1c after 3 months from baseline
Key secondary outcomes
1) Changes and %changes in HbA1c after 3, 6, 12, 18 and 24 months from baseline in the following parameters (excluding the value after 3 months): Fasting blood glucose or postprandial blood glucose (optional) and body weight.
2) Exploratory analyses
Stratified analyses by treatment (monotherapy vs combination therapy) and patient background (sex, baseline values, length of diabetes, BMI) etc. to identify patients who can benefit from glucose-lowering treatment with sitagliptin.
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Patients with type 2 diabetes who had received diet and exercise therapy or treatment with antidiabetic agents other than a DPP-4 inhibitor in addition to diet and exercise therapy for more than 1 month, and whose blood glucose has not been sufficiently controlled*.
2) Outpatients aged 20 years and above,, male and female.
3) Patients who have given written consent for the study
Key exclusion criteria
Patients who meet any of the following criteria will be excluded from the study.
1) Patients with type 1 diabetes
2) Patients who had a history of severe ketosis, diabetic coma or complete coma within previous 6 months
3) Patients before or after operation, and those with severe infections or serious injury
4) Patients with severe kidney dysfunction
5) Patients who had severe cardiovascular complications that require hospitalization within 6 months before signing the informed consent
6) Patients who are pregnant or maybe can pregnant and patients are lactating.
7) Patients with a history of hypersensitivity to the study drug
8) Patients who are considered not eligible for the study by the attending doctor due to other reasons
Target sample size
500
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Haruo Nishimura |
Organization
Osaka Saiseikai Nakatsu Hospital
Division name
Division of diabetes and endocrinology
Zip code
Address
2-10-39, Shibata, Kita-ku, Osaka-city
TEL
06-6372-0333
hnis@kuhp.kyoto-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Haruo Nishimura |
Organization
Osaka Saiseikai Nakatsu Hospital
Division name
Division of diabetes and endocrinology
Zip code
Address
2-10-39, Shibata, Kita-ku, Osaka-city
TEL
06-6372-0333
Homepage URL
23001@nakatsu.saiseikai.or.jp
Sponsor or person
Institute
Association for future management of diabetes
Institute
Department
Personal name
Funding Source
Organization
Research foundation for community medicine
Organization
Division
Category of Funding Organization
Non profit foundation
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Association for future management of diabetes
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
大阪府済生会中津病院(大阪府)、大阪府済生会茨木病院(大阪府)、馬場内科クリニック（大阪府）、市立岸和田市民病院（大阪府）、大歳内科（大阪府）、医仁会武田総合病院（京都府）、今村クリニック（大阪府）、大阪赤十字病院（大阪府）、大阪市立十三市民病院（大阪府）、大阪府立急性期・総合医療センター（大阪府）、大橋クリニック（大阪府）、奥田内科クリニック（大阪府）、近畿大学医学部奈良病院（奈良県）、神戸市立医療センター中央市民病院（兵庫県）、十条リハビリテーション病院（京都府）、センプククリニック（大阪府）、ふくだ内科クリニック（大阪府）
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 07 | Month | 18 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2010 | Year | 06 | Month | 15 | Day |
Date of IRB
Anticipated trial start date
| 2010 | Year | 07 | Month | 01 | Day |
Last follow-up date
| 2014 | Year | 12 | Month | 01 | Day |
Date of closure to data entry
| 2015 | Year | 01 | Month | 01 | Day |
Date trial data considered complete
| 2015 | Year | 02 | Month | 01 | Day |
Date analysis concluded
| 2015 | Year | 03 | Month | 01 | Day |
Other
Other related information
1) Changes and %changes in HbA1c after 3, 6, 12, 18 and 24 months from baseline in the following parameters (excluding the value after 3 months): Fasting blood glucose or postprandial blood glucose (optional) and body weight.
2) Exploratory analyses
Stratified analyses by treatment (monotherapy vs combination therapy) and patient background (sex, baseline values, length of diabetes, BMI) etc. to identify patients who can benefit from glucose-lowering treatment with sitagliptin.
Management information
Registered date
| 2011 | Year | 07 | Month | 18 | Day |
Last modified on
| 2016 | Year | 12 | Month | 12 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007091
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
